1
|
Khatir ZZ, Di Sotto A, Percaccio E, Tuylu Kucukkilinc T, Ercan A, Chippindale AM, Valipour M, Irannejad H. 4-{3-[(Pyridin-4-ylmethyl)amino]-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}phenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator. Arch Pharm (Weinheim) 2024; 357:e2300704. [PMID: 38442326 DOI: 10.1002/ardp.202300704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2023] [Revised: 02/02/2024] [Accepted: 02/08/2024] [Indexed: 03/07/2024]
Abstract
Hepatocellular carcinoma is the most common type of primary liver cancer. However, multidrug resistance (MDR) is a major obstacle to the effective chemotherapy of cancer cells. This report documents the rational design, synthesis, and biological evaluation of a novel series of triazolotriazines substituted with CH2NH-linked pyridine for use as dual c-Met/MDR inhibitors. Compound 12g with IC50 of 3.06 μM on HepG2 cells showed more potency than crizotinib (IC50 = 5.15 μM) in the MTT assay. In addition, 12g inhibited c-Met kinase at a low micromolar level (IC50 = 0.052 μM). 12g significantly inhibited P-gp and MRP1/2 efflux pumps in both cancerous HepG2 and BxPC3 cells starting from the lower concentrations of 3 and 0.3 µM, respectively. 12g did not inhibit MDR1 and MRP1/2 in noncancerous H69 cholangiocytes up to the concentration of 30 and 60 µM, respectively. Current results highlighted that cancerous cells were more susceptible to the effect of 12g than normal cells, in which the inhibition occurred only at the highest concentrations, suggesting a further interest in 12g as a selective anticancer agent. Overall, 12g, as a dual c-Met and P-gp/MRP inhibitor, is a promising lead compound for developing a new generation of anticancer agents.
Collapse
Affiliation(s)
- Zahra Zakeri Khatir
- Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| | - Antonella Di Sotto
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy
| | - Ester Percaccio
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy
| | - Tuba Tuylu Kucukkilinc
- Department of Biochemistry, Faculty of Pharmacy, Hacettepe University, Sihhiye, Ankara, Turkey
| | - Ayse Ercan
- Department of Biochemistry, Faculty of Pharmacy, Hacettepe University, Sihhiye, Ankara, Turkey
| | | | - Mehdi Valipour
- Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - Hamid Irannejad
- Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| |
Collapse
|
2
|
Yaragani M, Yadlapalli P, Raghavan S, Giridhar T, Mandava VBR, Singh RV, Kottapalli RP, Chinnusamy S. Electronic effect-dependent intramolecular non-covalent interactions on the activity of 4,4-dimethylimidazolidin-2-one pharmacophore-based androgen receptor antagonists. Chem Biol Drug Des 2023; 101:614-625. [PMID: 36198102 DOI: 10.1111/cbdd.14151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 09/15/2022] [Accepted: 09/30/2022] [Indexed: 11/30/2022]
Abstract
Because androgen receptor (AR) signalling is important for the development and progression of prostate cancer (PC), AR antagonists are utilized in clinical practices to treat PC and are referred to as androgen deprivation therapy (ADT). However, continued administration of AR antagonists often results in the development of resistance, known as castration-resistant prostate cancer (CRPC). Despite castration, it has been demonstrated that AR signalling continues to be fundamental to tumour growth. In this regard, a series of readily synthesizable 4,4-dimethylimidazolidine-2-one pharmacophore-based AR antagonists (FAR01-FAR11) were designed and synthesized. Androgen-dependent LNCaP PC cell line was used to test the AR-antagonist activity of these compounds in vitro and compared with the U.S. Food and Drug Administration (FDA) approved second-generation enzalutamide. In our previous work, rigid thiohydantoin pharmacophore in enzalutamide is replaced by the flexible 4,4-dimethylimidazolidin-2-one. In order to improve the flexibility further, one methylene group is introduced between the pharmacophore and one of the aromatic ring. Despite the fact that the amide functional group is a crucial characteristic for building AR antagonists, this class of molecules lacks one. FAR06 has the exact same activity as enzalutamide (IC50 : 0.782 μM) with an IC50 value of 0.801 μM among the series of compounds.
Collapse
Affiliation(s)
- Muralikrishna Yaragani
- Department of Chemistry, Koneru Lakshmaiah Education Foundation, Guntur, Andhra Pradesh, India
| | | | - Sriram Raghavan
- CAS in Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai, Tamil Nadu, India
| | - Thota Giridhar
- Sigma-Aldrich Chemicals Pvt. Ltd, Bangalure, Karnataka, India
| | | | | | | | - Saravanan Chinnusamy
- Center for Advanced Organic Materials (Sona-AROMA), Department of Chemistry, Sona College of Technology, Salem, Tamil Nadu, India
| |
Collapse
|
3
|
Sivakumar B, Ilango K. 5-Imidazolinone Derivatives as a Potent Pharmacological Agents—A Review. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2023. [DOI: 10.1134/s1068162023020140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
|
4
|
Fujii R, Yabushita M, Asada D, Tamura M, Nakagawa Y, Takahashi A, Nakayama A, Tomishige K. Continuous Flow Synthesis of 2-Imidazolidinone from Ethylenediamine Carbamate in Ethylenediamine Solvent over the CeO 2 Catalyst: Insights into Catalysis and Deactivation. ACS Catal 2023. [DOI: 10.1021/acscatal.2c05721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- Ryotaro Fujii
- Department of Applied Chemistry, School of Engineering, Tohoku University, 6-6-07 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi980-8579, Japan
- Organic Research Laboratory, Tosoh Corporation, Shunan, Yamaguchi746-8501, Japan
| | - Mizuho Yabushita
- Department of Applied Chemistry, School of Engineering, Tohoku University, 6-6-07 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi980-8579, Japan
| | - Daiki Asada
- Department of Chemical System Engineering, Graduate School of Engineering, The University of Tokyo, Tokyo113-8656, Japan
| | - Masazumi Tamura
- Department of Chemistry and Bioengineering, School of Engineering, Osaka Metropolitan University, Osaka558-8585, Japan
| | - Yoshinao Nakagawa
- Department of Applied Chemistry, School of Engineering, Tohoku University, 6-6-07 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi980-8579, Japan
| | - Atsushi Takahashi
- Department of Chemical Engineering, School of Engineering, Tohoku University, 6-6-07 Aoba, Aramaki, Sendai, Miyagi980-8579, Japan
| | - Akira Nakayama
- Department of Chemical System Engineering, Graduate School of Engineering, The University of Tokyo, Tokyo113-8656, Japan
| | - Keiichi Tomishige
- Department of Applied Chemistry, School of Engineering, Tohoku University, 6-6-07 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi980-8579, Japan
- Advanced Institute for Materials Research (WPI-AIMR), Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, Miyagi980-8577, Japan
| |
Collapse
|
5
|
Horsten T, Alegbejo Price TO, Van Meervelt L, Emery FDS, Dehaen W. 2-Imidazolidinone benzofurans as unexpected outcome of the Lewis acid mediated Nenitzescu reaction. NEW J CHEM 2022. [DOI: 10.1039/d1nj04965h] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Herein, a metal-free methodology towards 2-imidazolidinone benzofurans via piperazinone enaminoesters addition onto quinones and subsequent rearrangement has been disclosed.
Collapse
Affiliation(s)
- Tomas Horsten
- Molecular Design and Synthesis, Department of Chemistry, KU Leuven, Celestijnenlaan 200F, Leuven 3001, Belgium
| | - Temitayo Omowumi Alegbejo Price
- Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences at Ribeirao Preto of the University of Sao Paulo, Ribeirao Preto, SP, 14040-903, Brazil
| | - Luc Van Meervelt
- Biochemistry, Molecular and Structural Biology Section, Department of Chemistry, KU Leuven, Celestijnenlaan 200F, Leuven 3001, Belgium
| | - Flavio da Silva Emery
- Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences at Ribeirao Preto of the University of Sao Paulo, Ribeirao Preto, SP, 14040-903, Brazil
| | - Wim Dehaen
- Molecular Design and Synthesis, Department of Chemistry, KU Leuven, Celestijnenlaan 200F, Leuven 3001, Belgium
| |
Collapse
|
6
|
Hu KW, You X, Wang JZ, Wen X, Sun H, Xu QL, Lai Z. Chiral Phosphoric Acid Catalyzed Asymmetric Desymmetrization of para-Quinamines with Isocyanates: Access to Functionalized Imidazolidin-2-one Derivatives. Org Lett 2021; 23:7873-7877. [PMID: 34581589 DOI: 10.1021/acs.orglett.1c02889] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The development of enantioselective desymmetrization of para-quinamines with isocyanates catalyzed by chiral phosphoric acid is reported. The strategy provides concise access to functionalized imidazolidin-2-one derivatives in high yields and enantioselectivities under mild reaction conditions. Remarkably, this reaction could be performed on a gram scale using 5 mol % catalyst loading and the chiral imidazolidin-2-one derivatives could be easily transformed into valuable scaffolds without disturbing the enantiopurity, demonstrating the synthetic utility of this protocol.
Collapse
Affiliation(s)
- Kai-Wen Hu
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210000, China
| | - Xiao You
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210000, China
| | - Jin-Zheng Wang
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210000, China
| | - Xiaoan Wen
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210000, China
| | - Hongbin Sun
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210000, China
| | - Qing-Long Xu
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210000, China
| | - Zengwei Lai
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
| |
Collapse
|
7
|
Yaragani M, Yadlapalli P, Raghavan S, Thota G, Basaveswara Rao Mandava V, Vikram Singh R, Prasad Kottapalli R, Saravanan C. Discovery of Easily Synthesizable 4, 4‐Dimethylimidazolidin‐2‐ones as Potent Androgen Receptor Antagonists for Prostate Cancer. ChemistrySelect 2021. [DOI: 10.1002/slct.202101546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Affiliation(s)
- Muralikrishna Yaragani
- Department of Chemistry Koneru Lakshmaiah Education Foundation Guntur 522 502, Andhra Pradesh India
| | | | - Sriram Raghavan
- CAS in Crystallography and Biophysics University of Madras, Guindy Campus Chennai Tamil Nadu 600 020 India
| | - Giridhar Thota
- Sigma-Aldrich Chemicals Pvt. Ltd. Bangalure 560100 Karnataka India
| | | | | | | | - Chinnusamy Saravanan
- Center for Advanced Organic Materials (Sona-AROMA) Department of Chemistry Sona College of Technology Salem 636 005 Tamil Nadu India
| |
Collapse
|
8
|
Kaur N, Singh P, Banerjee P. Vinylogous Aza‐Michael Addition of Urea Derivatives with
p
‐Quinone Methides Followed by Oxidative Dearomative Cyclization: Approach to Spiroimidazolidinone Derivatives. Adv Synth Catal 2021. [DOI: 10.1002/adsc.202100077] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Navpreet Kaur
- Department of Chemistry Indian Institute of Technology Ropar Rupnagar Punjab 140001 India
| | - Priyanka Singh
- Department of Chemistry Indian Institute of Technology Ropar Rupnagar Punjab 140001 India
| | - Prabal Banerjee
- Department of Chemistry Indian Institute of Technology Ropar Rupnagar Punjab 140001 India
| |
Collapse
|
9
|
Duangjan C, Rukachaisirikul V, Kaeobamrung J. Synthesis of imidazolidin-2-ones via the cascade reactions of α-chloroaldoxime O-methanesulfonates. Tetrahedron Lett 2020. [DOI: 10.1016/j.tetlet.2020.152330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Kumar S, Jaipuri FA, Waldo JP, Potturi H, Marcinowicz A, Adams J, Van Allen C, Zhuang H, Vahanian N, Link C, Brincks EL, Mautino MR. Discovery of indoximod prodrugs and characterization of clinical candidate NLG802. Eur J Med Chem 2020; 198:112373. [PMID: 32422549 DOI: 10.1016/j.ejmech.2020.112373] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 04/20/2020] [Accepted: 04/21/2020] [Indexed: 12/20/2022]
Abstract
A series of different prodrugs of indoximod, including estesrs and peptide amides were synthesized with the aim of improving its oral bioavailability in humans. The pharmacokinetics of prodrugs that were stable in buffers, plasma and simulated gastric and intestinal fluids was first assessed in rats after oral dosing in solution or in capsule formulation. Two prodrugs that produced the highest exposure to indoximod in rats were further tested in Cynomolgus monkeys, a species in which indoximod has oral bioavailability of 6-10% and an equivalent dose-dependent exposure profile as humans. NLG802 was selected as the clinical development candidate after increasing oral bioavailability (>5-fold), Cmax (6.1-3.6 fold) and AUC (2.9-5.2 fold) in monkeys, compared to equivalent molar oral doses of indoximod. NLG802 is extensively absorbed and rapidly metabolized to indoximod in all species tested and shows a safe toxicological profile at the anticipated therapeutic doses. NLG802 markedly enhanced the anti-tumor responses of tumor-specific pmel-1 T cells in a melanoma tumor model. In conclusion, NLG802 is a prodrug of indoximod expected to increase clinical drug exposure to indoximod above the current achievable levels, thus increasing the possibility of therapeutic effects in a larger fraction of the target patient population.
Collapse
Affiliation(s)
| | | | | | - Hima Potturi
- NewLink Genetics, Ames, IA, 50010, United States
| | | | - James Adams
- NewLink Genetics, Ames, IA, 50010, United States
| | | | - Hong Zhuang
- NewLink Genetics, Ames, IA, 50010, United States
| | | | - Charles Link
- NewLink Genetics, Ames, IA, 50010, United States
| | - Erik L Brincks
- NewLink Genetics, Ames, IA, 50010, United States; Lumos Pharma, Inc., Ames, IA, 50010, United States.
| | | |
Collapse
|
11
|
Synthesis and antitumor activity of bis(arylsulfonyl)dihydroimidazolinone derivatives. Bioorg Med Chem Lett 2020; 30:126776. [PMID: 31704206 DOI: 10.1016/j.bmcl.2019.126776] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 10/20/2019] [Accepted: 10/23/2019] [Indexed: 12/24/2022]
Abstract
A series of novel bis(arylsulfonyl)dihydroimidazolinones with different aryl substitution patterns were readily synthesized and evaluated for their antitumor activities. Some of the newly synthesized compounds exhibited cytotoxicity at micromolar range against multiple cancer cell lines, including A549, HepG2, HuCCA-1, and MOLT-3. The most potent analogue contained pentafluorobenzenesulfonyl groups, which could be chemically elaborated to serve as a potential pharmacophore.
Collapse
|
12
|
Zeng YF, Duan YQ, Liao L, Long X, Gao C, Wen X. Synthesis and cytotoxic activity of 7,4’- O-modified genistein amino acid derivatives. JOURNAL OF CHEMICAL RESEARCH 2019. [DOI: 10.1177/1747519819871032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Fifteen 7,4’- O-modified genistein amino acid derivatives are synthesized through nucleophilic substitution and hydrolysis, followed by condensation with diverse amino acid esters. The antiproliferative activity of all the synthesized compounds is evaluated against three cancer cell lines (MGC-803, HeLa, HCT-116) and one normal cell line (HUVEC) using 5-fluorouracil (5-Fu) as the positive control. The results show that methyl [2-({5-hydroxy-3-[4-(2-{[3-(4-hydroxyphenyl)-1-methoxy-1-oxopropan-2-yl]amino}-2-oxoethoxy)phenyl]-4-oxo-4 H-chromen-7-yl}oxy)acetyl] tyrosinate exhibits significant antiproliferative activity against the MGC-803 cell line with an IC50 value of 8.52 µM, and its inhibitory effects on HeLa and HCT-116 cancer cells are stronger than that of the positive control drug 5-Fu.
Collapse
Affiliation(s)
- Yao-Fu Zeng
- Institute of Pharmacy and Pharmacology, University of South China, Hengyang, P. R. China
- Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, P. R. China
| | - Yu-Qin Duan
- Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, P. R. China
| | - Lanqing Liao
- Institute of Pharmacy and Pharmacology, University of South China, Hengyang, P. R. China
| | - Xiaokang Long
- Institute of Pharmacy and Pharmacology, University of South China, Hengyang, P. R. China
| | - Cheng Gao
- Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, P. R. China
| | - Xianghao Wen
- Affiliated Nanhua Hospital, University of South China, Hengyang, P. R. China
| |
Collapse
|
13
|
Sanches BM, Ferreira EI. Is prodrug design an approach to increase water solubility? Int J Pharm 2019; 568:118498. [DOI: 10.1016/j.ijpharm.2019.118498] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 07/04/2019] [Accepted: 07/05/2019] [Indexed: 02/07/2023]
|
14
|
de Oliveira Pedrosa Rolim M, de Almeida AR, da Rocha Pitta MG, de Melo Rêgo MJB, Quintans-Júnior LJ, de Souza Siqueira Quintans J, Heimfarth L, Scotti L, Scotti MT, da Cruz RMD, de Almeida RN, da Silva TG, de Oliveira JA, de Campos ML, Marchand P, Mendonça-Junior FJB. Design, synthesis and pharmacological evaluation of CVIB, a codrug of carvacrol and ibuprofen as a novel anti-inflammatory agent. Int Immunopharmacol 2019; 76:105856. [PMID: 31480005 DOI: 10.1016/j.intimp.2019.105856] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Revised: 08/18/2019] [Accepted: 08/20/2019] [Indexed: 01/23/2023]
Abstract
The search for new drugs with anti-inflammatory properties remains a challenge for modern medicine. Among the various strategies for drug discovery, deriving new chemical entities from known bioactive natural and/or synthetic compounds remains a promising approach. Here, we designed and synthesized CVIB, a codrug developed by association of carvacrol (a phenolic monoterpene) with ibuprofen (a non-steroidal anti-inflammatory drug). In silico pharmacokinetic and physicochemical properties evaluation indicated low aqueous solubility (LogP ≥5.0). Nevertheless, the hybrid presented excellent oral bioavailability, gastrointestinal tract absorption, and low toxicity. CVIB did not present cytotoxicity in peripheral blood mononuclear cells (PBMCs), and promoted a significant reduction in IL-2, IL-10, IL-17, and IFN-γ cytokine levels in vitro. The LD50 was estimated to be approximately 5000 mg/kg. CVIB was stable and detectable in human plasma after 24 h. In vivo anti-inflammatory evaluations revealed that CVIB at 10 and 50 mg/kg i.p. caused a significant decrease in total leukocyte count (p < 0.01) and provoked a significant reduction in IL-1β (p < 0.01). CVIB at 10 mg/kg i.p. efficiently decreased inflammatory parameters better than the physical mixture (carvacrol + ibuprofen 10 mg/kg i.p.). The results suggest that the codrug approach is a good option for drug design and development, creating the possibility of combining NSAIDs with natural products in order to obtain new hybrid drugs may be useful for treatment of inflammatory diseases.
Collapse
Affiliation(s)
- Michelle de Oliveira Pedrosa Rolim
- Laboratory of Synthesis and Drug Delivery, State University of Paraiba, João Pessoa, PB 58071-160, Brazil; Post-Graduation Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba, João Pessoa, PB 58051-900, Brazil
| | - Anderson Rodrigues de Almeida
- Laboratory of Immunomodulation and Novel Therapeutic Approaches, Federal University of Pernambuco, Recife, PE 50670-901, Brazil
| | - Maira Galdino da Rocha Pitta
- Laboratory of Immunomodulation and Novel Therapeutic Approaches, Federal University of Pernambuco, Recife, PE 50670-901, Brazil
| | | | - Lucindo José Quintans-Júnior
- Laboratory of Neurosciences and Pharmacological Assays (LANEF) University of Sergipe, São Cristóvão, SE 49100-000, Brazil
| | | | - Luana Heimfarth
- Laboratory of Neurosciences and Pharmacological Assays (LANEF) University of Sergipe, São Cristóvão, SE 49100-000, Brazil
| | - Luciana Scotti
- Post-Graduation Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba, João Pessoa, PB 58051-900, Brazil; Teaching and Research Management - University Hospital, Federal University of Paraiba, João Pessoa, PB 58051-900, Brazil
| | - Marcus Tullius Scotti
- Post-Graduation Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba, João Pessoa, PB 58051-900, Brazil
| | - Ryldene Marques Duarte da Cruz
- Post-Graduation Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba, João Pessoa, PB 58051-900, Brazil
| | - Reinaldo Nóbrega de Almeida
- Post-Graduation Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba, João Pessoa, PB 58051-900, Brazil
| | - Teresinha Gonçalves da Silva
- Department of Antibiotics, Center for Biosciences, Federal University of Pernambuco, Recife, PE 50740-520, Brazil
| | - Jonata Augusto de Oliveira
- Laboratory of Toxicology, São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, SP 14801-902, Brazil
| | - Michel Leandro de Campos
- Health Research and Education Center (NUPADS), Federal University of Mato Grosso, Sinop, MT 78550-728, Brazil
| | - Pascal Marchand
- Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, F-44000 Nantes, France
| | - Francisco Jaime Bezerra Mendonça-Junior
- Laboratory of Synthesis and Drug Delivery, State University of Paraiba, João Pessoa, PB 58071-160, Brazil; Post-Graduation Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba, João Pessoa, PB 58051-900, Brazil.
| |
Collapse
|
15
|
Pal K, Sontakke GS, Volla CMR. Rh(II)-Catalyzed Highly Diastereoselective Cascade Transannulation of N-Sulfonyl-1,2,3-triazoles and Vinyl Benzoxazinanones. Org Lett 2019; 21:3716-3720. [DOI: 10.1021/acs.orglett.9b01174] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Kuntal Pal
- Department of Chemistry, Indian Institute of Technology Bombay, Powai, Mumbai-400076, India
| | - Geetanjali S. Sontakke
- Department of Chemistry, Indian Institute of Technology Bombay, Powai, Mumbai-400076, India
| | - Chandra M. R. Volla
- Department of Chemistry, Indian Institute of Technology Bombay, Powai, Mumbai-400076, India
| |
Collapse
|
16
|
Casnati A, Perrone A, Mazzeo PP, Bacchi A, Mancuso R, Gabriele B, Maggi R, Maestri G, Motti E, Stirling A, Ca' ND. Synthesis of Imidazolidin-2-ones and Imidazol-2-ones via Base-Catalyzed Intramolecular Hydroamidation of Propargylic Ureas under Ambient Conditions. J Org Chem 2019; 84:3477-3490. [PMID: 30788963 DOI: 10.1021/acs.joc.9b00064] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The first organo-catalyzed synthesis of imidazolidin-2-ones and imidazol-2-ones via intramolecular hydroamidation of propargylic ureas is reported. The phosphazene base BEMP turned out to be the most active organo-catalyst compared with guanidine and amidine bases. Excellent chemo- and regioselectivities to five-membered cyclic ureas have been achieved under ambient conditions, with a wide substrate scope and exceptionally short reaction times (down to 1 min). A base-mediated isomerization step to an allenamide intermediate is the most feasible reaction pathway to give imidazol-2-ones, as suggested by DFT studies.
Collapse
Affiliation(s)
- Alessandra Casnati
- Department of Chemistry, Life Sciences and Environmental Sustainability , University of Parma , 43124 Parma , Italy
| | - Antonio Perrone
- Department of Chemistry, Life Sciences and Environmental Sustainability , University of Parma , 43124 Parma , Italy
| | - Paolo P Mazzeo
- Department of Chemistry, Life Sciences and Environmental Sustainability , University of Parma , 43124 Parma , Italy.,Biopharmanet-tec , Parco delle Scienze, 27/A , 43124 Parma , Italy
| | - Alessia Bacchi
- Department of Chemistry, Life Sciences and Environmental Sustainability , University of Parma , 43124 Parma , Italy.,Biopharmanet-tec , Parco delle Scienze, 27/A , 43124 Parma , Italy
| | - Raffaella Mancuso
- Dipartimento di Chimica e Tecnologie Chimiche , Università della Calabria , 87036 Arcavacata di Rende, Cosenza , Italy
| | - Bartolo Gabriele
- Dipartimento di Chimica e Tecnologie Chimiche , Università della Calabria , 87036 Arcavacata di Rende, Cosenza , Italy
| | - Raimondo Maggi
- Department of Chemistry, Life Sciences and Environmental Sustainability , University of Parma , 43124 Parma , Italy
| | - Giovanni Maestri
- Department of Chemistry, Life Sciences and Environmental Sustainability , University of Parma , 43124 Parma , Italy
| | - Elena Motti
- Department of Chemistry, Life Sciences and Environmental Sustainability , University of Parma , 43124 Parma , Italy
| | - András Stirling
- Theoretical Chemistry Research Group, Institute of Organic Chemistry , Research Centre for Natural Sciences , Budapest , Hungary
| | - Nicola Della Ca'
- Department of Chemistry, Life Sciences and Environmental Sustainability , University of Parma , 43124 Parma , Italy
| |
Collapse
|
17
|
Recent Advances in the Catalytic Synthesis of Imidazolidin-2-ones and Benzimidazolidin-2-ones. Catalysts 2019. [DOI: 10.3390/catal9010028] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
2-Imidazolidinone and its analogues are omnipresent structural motifs of pharmaceuticals, natural products, chiral auxiliaries, and intermediates in organic syntheses. Over the years, continuous efforts have been addressed to the development of sustainable and more efficient protocols for the synthesis of these heterocycles. This review gives a summary of the catalytic strategies to access imidazolidin-2-ones and benzimidazolidin-2-ones that have appeared in the literature from 2010 to 2018. Particularly important contributions beyond the timespan will be mentioned. The review is organized in four main chapters that identify the most common approaches to imidazolidin-2-one derivatives: (1) the direct incorporation of the carbonyl group into 1,2-diamines, (2) the diamination of olefins, (3) the intramolecular hydroamination of linear urea derivatives and (4) aziridine ring expansion. Methods not included in this classification will be addressed in the miscellaneous section.
Collapse
|
18
|
Vicente-Blázquez A, González M, Álvarez R, Del Mazo S, Medarde M, Peláez R. Antitubulin sulfonamides: The successful combination of an established drug class and a multifaceted target. Med Res Rev 2018; 39:775-830. [PMID: 30362234 DOI: 10.1002/med.21541] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Revised: 09/02/2018] [Accepted: 09/06/2018] [Indexed: 12/13/2022]
Abstract
Tubulin, the microtubules and their dynamic behavior are amongst the most successful antitumor, antifungal, antiparasitic, and herbicidal drug targets. Sulfonamides are exemplary drugs with applications in the clinic, in veterinary and in the agrochemical industry. This review summarizes the actual state and recent progress of both fields looking from the double point of view of the target and its drugs, with special focus onto the structural aspects. The article starts with a brief description of tubulin structure and its dynamic assembly and disassembly into microtubules and other polymers. Posttranslational modifications and the many cellular means of regulating and modulating tubulin's biology are briefly presented in the tubulin code. Next, the structurally characterized drug binding sites, their occupying drugs and the effects they induce are described, emphasizing on the structural requirements for high potency, selectivity, and low toxicity. The second part starts with a summary of the favorable and highly tunable combination of physical-chemical and biological properties that render sulfonamides a prototypical example of privileged scaffolds with representatives in many therapeutic areas. A complete description of tubulin-binding sulfonamides is provided, covering the different species and drug sites. Some of the antimitotic sulfonamides have met with very successful applications and others less so, thus illustrating the advances, limitations, and future perspectives of the field. All of them combine in a mechanism of action and a clinical outcome that conform efficient drugs.
Collapse
Affiliation(s)
- Alba Vicente-Blázquez
- Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Facultad de Farmacia, Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Facultad de Farmacia, Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
| | - Myriam González
- Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Facultad de Farmacia, Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Facultad de Farmacia, Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain
| | - Raquel Álvarez
- Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Facultad de Farmacia, Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Facultad de Farmacia, Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain
| | - Sara Del Mazo
- Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Facultad de Farmacia, Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Facultad de Farmacia, Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain
| | - Manuel Medarde
- Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Facultad de Farmacia, Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Facultad de Farmacia, Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain
| | - Rafael Peláez
- Laboratorio de Química Orgánica y Farmacéutica, Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Facultad de Farmacia, Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.,Facultad de Farmacia, Centro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain
| |
Collapse
|
19
|
Marchegiani M, Nodari M, Tansini F, Massera C, Mancuso R, Gabriele B, Costa M, Della Ca’ N. Urea derivatives from carbon dioxide and amines by guanidine catalysis: Easy access to imidazolidin-2-ones under solvent-free conditions. J CO2 UTIL 2017. [DOI: 10.1016/j.jcou.2017.08.017] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
20
|
Jiang Y, Li X, Hou J, Huang Y, Jia Y, Zou M, Zhang J, Wang X, Xu W, Zhang Y. Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent. Eur J Med Chem 2016; 121:649-657. [PMID: 27322756 DOI: 10.1016/j.ejmech.2016.05.068] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Revised: 05/29/2016] [Accepted: 05/30/2016] [Indexed: 11/17/2022]
Abstract
We designed and synthesized a novel mutual prodrug, named BC-01 (3), by integrating ubenimex and Fluorouracil (5-FU) into one molecule based on prior research results that showed that a combination of the aminopeptidase N (CD13) inhibitor, ubenimex, and the cytotoxic antitumor agent, 5-FU, exhibited improved in vitro and in vivo antitumor efficiency. 3 showed potent inhibitory activity against CD13 enzymatic activity. Compared with ubenimex, 3 exhibited more potent anti-angiogenesis effects, and compared with the approved 5-FU prodrug, capecitabine, 3 exhibited more potent tumor growth inhibitory and anti-metastasis effects. Additionally, compared with 5-FU or 5-FU plus ubenimex, 3 also exhibited a superior antitumor efficiency even in our 5-FU-resistant mice model. Other antitumor agents could be conjugated with ubenimex using this strategy to obtain novel mutual prodrugs with promising antitumor potency.
Collapse
Affiliation(s)
- Yuqi Jiang
- Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji'nan, Shandong, 250012, PR China
| | - Xiaoyang Li
- Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji'nan, Shandong, 250012, PR China
| | - Jinning Hou
- Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji'nan, Shandong, 250012, PR China
| | - Yongxue Huang
- Weifang Bochuang International Biological Medicinal Institute, Weifang, Shandong, 261061, PR China
| | - Yuping Jia
- Shandong Academy of Pharmaceutical Sciences, Ji'nan, Shandong, 250101, PR China
| | - Mingming Zou
- Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji'nan, Shandong, 250012, PR China
| | - Jian Zhang
- College of Pharmacy, Weifang Medical University, 261053, Wei'fang, Shandong, PR China
| | - Xuejian Wang
- College of Pharmacy, Weifang Medical University, 261053, Wei'fang, Shandong, PR China.
| | - Wenfang Xu
- Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji'nan, Shandong, 250012, PR China.
| | - Yingjie Zhang
- Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji'nan, Shandong, 250012, PR China.
| |
Collapse
|
21
|
The Prodrug Approach: A Successful Tool for Improving Drug Solubility. Molecules 2015; 21:42. [PMID: 26729077 PMCID: PMC6273601 DOI: 10.3390/molecules21010042] [Citation(s) in RCA: 150] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Revised: 12/10/2015] [Accepted: 12/15/2015] [Indexed: 12/04/2022] Open
Abstract
Prodrug design is a widely known molecular modification strategy that aims to optimize the physicochemical and pharmacological properties of drugs to improve their solubility and pharmacokinetic features and decrease their toxicity. A lack of solubility is one of the main obstacles to drug development. This review aims to describe recent advances in the improvement of solubility via the prodrug approach. The main chemical carriers and examples of successful strategies will be discussed, highlighting the advances of this field in the last ten years.
Collapse
|
22
|
Tabarki MA, Besbes R. Ring expansion of aziridine-2-carboxylates. An efficient entry to imidazolidin-2-ones and oxazolidin-2-imines. Tetrahedron Lett 2015. [DOI: 10.1016/j.tetlet.2015.02.085] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|